Skip to search formSkip to main contentSkip to account menu

OSI 906

Known as: OSI-906, IGF-1R inhibitor OSI-906, OSI906 
National Institutes of Health

Related topics

Related topics

1 relation
linsitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Antitumor effect of insulin‐like growth factor‐1 receptor inhibition in head and neck squamous cell carcinoma
The insulin‐like growth factor‐1 receptor (IGF1R) has been implicated in therapeutic resistance in head and neck squamous cell… 
2016
2016
Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors.
2559 Background: OSI-906 is a potent small molecule inhibitor of IGF-1R, a receptor tyrosine kinase activated by insulin like… 
2015
2015
Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474
Drug resistance often critically limits the efficacy of molecular targeted drugs. Although pharmacological inhibition of… 
Review
2014
Review
2014
International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI-906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC).
4507 Background: ACC is an uncommon but frequently fatal cancer. For pts with metastatic or recurrent nonoperable ACC, there are… 
2014
2014
Study of the Selectivity of Insulin-Like Growth Factor-1 Receptor (IGF1R) Inhibitors
The insulin-like growth factor-1 receptor (IGF1R) is a drug target for oncology, and many studies are ongoing to identify… 
2013
2013
A phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
197 Background: Novel agents capable of blocking AR ligand independent pathways responsible for the development of CRPC are… 
2011
2011
A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced…
3099 Background: OSI-906 is an oral inhibitor of IGF-1R and IR. Increased IGF-1R and IR activity is observed in human cancers and… 
2010
2010
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid…
3098^ Background: OSI-906 is an oral inhibitor of IGF-1R and IR tyrosine kinases. IGF-1R:EGFR cross-talk contributes to… 
2007
2007
In vivo evaluation of OSI-906, a novel small molecule kinase inhibitor of the insulin-like growth factor-1 receptor (IGF-1R)
B244 The insulin-like growth factor-1 receptor (IGF-1R) has emerged as a potentially viable target for the development of novel… 
2007
2007
Inhibition of IGF-1R by OSI-906 potentiates efficacy of various molecular targeted agents by blocking feedback loops converging at the level of IRS-1
PR-1 The receptor for insulin-like growth factor (IGF-1R) is a critical mediator of tumor cell survival through its strong… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)